Decrease (-) Restore Default Increase (+)
Bookmark and Share
clear spacerNorton Healthcare Quality Report

Other Indicators


This section displays miscellaneous death rates that do not fit clearly elsewhere. Norton Healthcare performance represents the performance of all the hospitals combined.

Inpatients who die - percent of patients with
Number of gastrointestinal (GI) hemorrhage patients per 100, who died in the hospital. Risk-adjusted using patient age, severity of illness, and risk of mortality (APR-DRG version 20). Includes inpatients 18 years and older discharged with a principal diagnosis of GI hemorrhage. Excludes patients with missing discharge dispositions or patients transferred to an acute care hospital.(AHRQ IQI 18) GI hemorrhage (AHRQ risk-adj.) low 0.9 0.8 0.8 1.4   0.9   2.4
Number of hip fracture patients per 100, who died in the hospital. Risk-adjusted using patient age, severity of illness, and risk of mortality (APR-DRG version 20). Includes inpatients 65 years and older discharged with a principal diagnosis of hip fracture. Excludes patients with missing discharge dispositions or patients transferred to an acute care hospital.(AHRQ IQI 19) hip fracture (AHRQ risk-adj.) low 1.6 1.2 4.8 1.1   1.6   2.8
Blood Clot Prevention - % of patients
Number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after hospital admission or surgery. Hospitalized patients are at risk for developing blood clots. Routine evaluation of hospitalized patients at risk and appropriate prophylaxis administration have been proven to reduce and prevent VTE events. Includes all discharged hospital inpatients. Excludes patients less than 18 years of age, patients with length of stay less than 2 days and greater than 120 days, patients with comfort measures only documented, patients directly admitted to the ICU or transferred to the ICU, patients with principal diagnosis of mental disorders or stroke, and patients with principal or secondary diagnosis of obstetrics or defined VTE(NQF 0371/ JC/ CMS VTE-1) who received VTE prophylaxis to prevent blood clots high 85.4 93.1 81.0 78.7 # 82.9   91.6
Number of patients who received VTE prophylaxis or have documentation why no VTE prophylaxis was given the day of or the day after ICU admission (or transfer) or the day of or the day after surgery after ICU admission (or transfer). Admission to the ICU puts patients at an increased risk for developing VTE. Routine evaluation of hospitalized patients at risk and appropriate prophylaxis administration have been proven to reduce and prevent VTE events. Includes patients directly admitted or transferred to ICU. Excludes patients less than 18 years of age, patients with length of stay less than 2 days and greater than 120 days, patients with comfort measures only documented, patients with ICU LOS les than 1 day without VTE prophylaxis administered and documented reason for no VTE prophylaxis, and patients with principal or secondary diagnosis of obstetrics or defined VTE.(NQF 0372/ JC/ CMS VTE-2) ICU patients who received VTE prophylaxis to prevent blood clots high 97.4 # 88.9 # # 92.4   95.0
Number of patients diagnosed with confirmed VTE who received warfarin and perenteral anticoagulation: ? Five or more days, with an INR greater than or equal to 2 prior to discontinuation of parenteral therapy OR ? Five or more days, with an INR less than 2 and discharged on overlap therapy OR ? Less than five days and discharged on overlap therapy OR ? With documentation of reason for discontinuation of overlap therapy OR ? With documentation of a reason for no overlap therapy Includes patients with confirmed VTE who received warfarin. Excludes patients less than 18 years of age, patients with length of stay greater than 120 days, patients with comfort measures documented, patients discharged to a health care facility for hospice care or home for hospice care, patients who expired, patients who left against medical advice, patients discharged to another hospital, patients without warfarin therapy during hospital stay, and patients without VTE confirmed by diagnostic testing.(NQF 0373/ JC/ CMS VTE-3) with Venous Thromboembolism who received warfarin and parenteral anticoagulation high 88.4 100.0Quality Ribbon 87.5 90.5 # 89.8   95.9
Number of patients who have their IV UFH therapy dosages and platelet counts monitored according to defined parameters such as a nomogram or protocol. Includes patient with confirmed VTE receiving IV UFH therapy. Excludes patients less than 18 years of age, patients with length of stay greater than 120 days, patients with comfort measures only documented, patients discharged to a health care facility for hospice care or home for hospice care, patients who expired, patients who left against medical advice, patients discharged to another hospital, patients without UFH therapy administration, and patients without VTE confirmed by diagnostic testing.(JC/ CMS VTE-4) with Venous Thromboembolism given heparin with platelet counts monitoring high 97.8 # 98.6 100.0Quality Ribbon # 98.7   97.9
Number of patients with documentation that they or their caregivers were given written discharge instructions or other educational material about warfarin that addressed all four criteria: compliance issues, dietary advice, follow-up monitoring, and potential for adverse drug reactions and interactions. Patient education achieve successful outcomes, reduce hospital readmissions, and may reduce the risk of adverse drug events. Includes patients with confirmed VTE discharged on warfarin therapy. Excludes patients less than 18 years of age, patients with length of stay greater than 120 days, patients without warfarin prescribed at discharge, and patients without VTE confirmed by diagnostic testing.(JC / CMS VTE-5) given written discharge instructions about warfarin therapy high 69.0 # 10.0 18.2 # 32.6   83.0
Number of patients diagnosed with confirmed VTE during hospitalization who did not receive VTE prophylaxis prior to the VTE diagnostic test order date. Includes patients who developed confirmed VTE during the hospital stay. Excludes patients less than 18 years of age, patients with length of stay greater than 120 days, patients with comfort measures only documented, patients with principal diagnosis of VTE, patients with VTE present on admission, patients with reason for not administering mechanical and pharmacological prophylaxis, and patients without VTE confirmed by diagnostic testing.(JC / CMS VTE-6) who developed a blood clot while in the hospital and received no VTE prophylaxis low # # 9.7 # # 11.5 15.0 10.0

Medical Care

Cancer
Pregnancy & Prenatal Classes
Weight Loss
Orthopedics
Heart Disease
Neurology
Women's Health
More Medical Care

Locations

Hospitals
Immediate Care
Health Centers
Emergency Room
Doctors Offices
Specialists
Affiliate Hospitals

Patients and Visitors

MyChart
Pay Your Bill
Request an Appointment
Get Healthy
Support Groups
Fitness Groups
Mobile Applications
Clinical Trials
Online Nursery
Classes and Events
Send an eCard
Patient Stories
Places to Stay

About Us

Quality Report 
Careers
Ways to Help
Community Outreach
Contact Us
(502) 629-1234

Connect with us

© 2014 Norton Healthcare
Serving Kentucky and Southern Indiana